AETNA VARIABLE PORTFOLIOS INC
PRES14A, 2000-04-12
Previous: PEGASUS COMMUNICATIONS CORP, 424B3, 2000-04-12
Next: AETNA VARIABLE PORTFOLIOS INC, PRES14A, 2000-04-12





                                  SCHEDULE 14A
                                 (RULE 14A-101)
                     INFORMATION REQUIRED IN PROXY STATEMENT
                            SCHEDULE 14A INFORMATION
           Proxy Statement Pursuant to Section 14(a) of the Securities
                     Exchange Act of 1934 (Amendment No.__ )

Filed by the Registrant                         X
Filed by a Party other than the Registrant
                  Check the appropriate box:    __

X       Preliminary Proxy Statement            __     Confidential, for Use of
                                                       the Commission Only
                                                       (as permitted by
                                                       Rule 14a-6(e)(2))
__      Definitive Proxy Statement
__      Definitive additional materials
__      Soliciting material pursuant to Rule 14a-11(c) or Rule 14a-12

                         AETNA VARIABLE PORTFOLIOS, INC.
      (Name of Registrant as Specified in Its Charter/Declaration of Trust)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

               Payment of filing fee (Check the appropriate box):

X        No fee required.
__       Fee  computed on table below per  Exchange  Act Rules  14a-6(i)(4)  and
0-11.

(1)  Title of each class of securities to which transaction applies:

(2)  Aggregate number of securities to which transaction applies:

(3)  Per unit price or other underlying value of transaction  computed  pursuant
     to Exchange  Act Rule 0-11 (Set forth the amount on which the filing fee is
     calculated and state how it was determined):

(4)  Proposed maximum aggregate value of transaction:

(5)  Total fee paid:

__       Fee paid previously with preliminary materials:

__       Check box if any part of the fee is offset as provided by Exchange  Act
         Rule  0-11(a)(2)  and identity the filing for which the  offsetting fee
         was paid  previously.  Identify  the  previous  filing by  registration
         statement number, or the form or schedule and the date of its filing.

(1)  Amount previously paid:

(2)  Form, Schedule or Registration Statement no.:

(3)  Filing Party:

(4)  Date Filed:



<PAGE>


                                               J. Scott Fox
                                               President
                                               Aetna Variable Portfolios,  Inc.



May 30, 2000


Dear Contract Holder/Participant:

     I am  writing  to let you  know  that,  as  stated  in the  enclosed  Proxy
Statement,  a special  shareholder  meeting will be held on July 28,  2000.  The
purpose of the  meeting is for you to vote on a proposal  to (1)  liquidate  one
portfolio of Aetna Variable Portfolios,  Inc. ("the Company"):  Aetna Index Plus
Bond VP; (2) amend the Company's  charter to reflect this  liquidation;  and (3)
substitute  assets  remaining in the liquidating fund as of the liquidation date
with interests in Aetna Money Market VP.

     On March 1, the Board of  Directors  for Aetna  Variable  Portfolios,  Inc.
considered and agreed to submit this proposal to  shareholders.  (This portfolio
was closed to new investment on May 15.) If approved by shareholders at the July
28 meeting,  the liquidation will occur no later than September 1, 2000. You may
transfer your assets into another fund within your plan at any time prior to the
liquidation  date.  If you do not do so,  however,  please note that your assets
will automatically be transferred into Aetna Money Market VP.

     THE BOARD OF DIRECTORS RECOMMENDS  THAT SHAREHOLDERS APPROVE THE PROPOSAL
DESCRIBED IN THE ENCLOSED PROXY STATEMENT.  Their  recommendation  is based on a
number of factors,  including  the  portfolio's  inability  to sell a sufficient
number of shares to lower operating expenses, and poor sales trends. The reasons
for  recommending  this  course of action are  described  in detail in the Proxy
Statement, which you should consider carefully before casting your vote.

          PLEASE  VOTE AND RETURN YOUR PROXY CARD IN THE  ENCLOSED  POSTAGE-PAID
ENVELOPE  AS SOON AS  POSSIBLE.  Your vote is  critical,  no matter how large or
small your holdings may be.

     If you have any  questions  before you vote,  please  call  1-800-677-4636.
We'll  help  you  get  the  answers  you  need  promptly.  Thank  you  for  your
participation in this important matter.

Sincerely,

/S/ J. SCOTT FOX
J. Scott Fox
(enclosures)


<PAGE>

                           NOTICE OF A SPECIAL MEETING
                             OF THE SHAREHOLDERS OF

                         AETNA VARIABLE PORTFOLIOS, INC.
                            Aetna Index Plus Bond VP

     A Special Meeting of the Shareholders (the "Special Meeting") of Aetna
Index Plus Bond VP (the "Fund"),  a series of Aetna  Variable  Portfolios,  Inc.
(the "Company"),  will be held on July 28, 2000, at 10:00 a.m., Eastern time, at
10 State  House  Square,  Hartford,  Connecticut  06103-3602  for the  following
purposes:

     1. to consider and vote on a Plan of Liquidation and a Plan of Substitution
     for the Fund and,  in  connection  with the Plan of  Liquidation,  proposed
     amendments  to the  Charter of the  Company,  as set forth in  Articles  of
     Amendment; and


     2. to transact such other  business as may properly come before the Special
     Meeting and any adjournments thereof.

         Please read the enclosed  proxy  statement  carefully  for  information
concerning the proposal to be considered at the Special Meeting.

         Shareholders  of  record at the  close of  business  on May 1, 2000 are
entitled  to notice of and to vote at the  Special  Meeting.  You are invited to
attend the Special  Meeting.  If you cannot do so, however,  please complete and
sign the enclosed authorization card, and return it in the accompanying envelope
as promptly as possible.  Any shareholder attending the Special Meeting may vote
in person even though an authorization card has already been returned.

                                         By Order of the Board of Directors,


                                          Amy R. Doberman
                                          Secretary


May 30, 2000


<PAGE>



                              PRELIMINARY COPIES

                         AETNA VARIABLE PORTFOLIOS, INC.
                            Aetna Index Plus Bond VP

                                 PROXY STATEMENT
                                  May 30, 2000

          This Proxy  Statement  provides  information  you should review before
voting on the matter  listed in the Notice of  Special  Meeting on the  previous
page for Aetna  Index  Plus  Bond VP (the  "Fund"),  a series of Aetna  Variable
Portfolios, Inc. (the "Company"). The Company's Board of Directors (the "Board")
is soliciting  your vote for a Special  Meeting of Shareholders of the Fund (the
"Special  Meeting") to be held at 10 State House Square,  Hartford,  Connecticut
06103-3602,  on July 28, 2000, at 10:00 a.m.,  Eastern time, and, if the Special
Meeting is adjourned, at any adjournment of that Meeting.

         This Proxy Statement  describes the matter that will be voted on at the
Special  Meeting  (the  "Proposal").  The  solicitation  of votes is made by the
mailing of this Proxy Statement and the  accompanying  authorization  card on or
about May 30, 2000. Aeltus Investment  Management,  Inc. ("Aeltus"),  the Fund's
investment   adviser,  or  its  affiliates  may  contact  Contract  Holders  and
participants  with an interest in the Fund,  commencing in June 2000, to discuss
the Proposal.  The expenses  incurred in connection  with  preparing  this Proxy
Statement and its enclosures and of all solicitations will be paid by Aeltus.

         A copy of the  Company's  Annual  Report  for  the  fiscal  year  ended
December 31, 1999, was mailed to annuity  Contract Holders having an interest in
the Fund on or about February 26, 2000. This Proxy  Statement  should be read in
conjunction  with  that  Annual  Report.  The  Company's  Annual  Report is also
available upon request. You can obtain a copy of the Company's Annual Report and
any more recent Semi-Annual Report, without charge, by writing to the Company at
151   Farmington   Avenue,   Hartford,   Connecticut   06156,   or  by   calling
1-800-525-4225.

          Shareholders of record on May 1, 2000 (the "record date") are entitled
to be present and to vote at the Special Meeting or any adjourned meeting. As of
the record date, the Fund had [ ] shares

         Other  than  shares  purchased  by Aetna  Life  Insurance  and  Annuity
Company's  general  account in connection  with  providing  seed capital for the
Fund, shares of the Fund are offered only to insurance company separate accounts
that fund both  annuity and life  insurance  contracts.  As of the record  date,
Aetna Life Insurance and Annuity  Company  ("Aetna")  owned of record all of the
shares of the Fund  (100%).*  Of this  amount,  [ ] shares of the Fund ( %) were
allocated to Aetna's general account.

*         Aetna,  as the  legal  owner  of  the  shares,  has  sole  voting  and
          investment power with respect to the shares.  Aetna's principal office
          is located at 151 Farmington Avenue, Hartford, Connecticut 06156-8962.

         The  remaining [ ] shares of the Fund ( %) were held by Aetna on behalf
of Variable  Annuity Account C, a separate  account that funds variable  annuity
contracts  (each a "Contract")  issued to individual or group  Contract  holders
("Contract Holders").

         The  separate  account  invests  in  the  Fund.  Contract  Holders  (or
participants  under  group  contracts  as  applicable)  who  select the Fund for
investment through a Contract have a beneficial interest in the Fund, but do not
invest directly in or hold shares of the Fund.  Aetna, on behalf of the separate
account,  is the true  shareholder  of the Fund, but generally will pass through
any voting rights to Contract Holders. Contract Holders therefore have the right
to instruct Aetna how to vote their interest with respect to the Proposal. Aetna
will vote the shares of the Fund held in Aetna's name for the  separate  account
as directed by the Contract Holder.  The holders of certain group Contracts have
the right to direct the vote for all shares under the respective Contract,  for,
against or abstaining,  in the same proportions as shares for which instructions
have been given by participants covered by the Contract. This proxy statement is
used to solicit instructions for voting shares of the Fund. All persons entitled
to direct the voting of shares, whether they are Contract Holders,  participants
or  shareholders,  will be  described  as  voting  for  purposes  of this  Proxy
Statement.

         With respect to Fund shares held by the separate account, if Aetna does
not receive voting  instructions for any shares held under the Contracts,  Aetna
will vote those separate account shares for, against or abstaining,  in the same
proportions as the shares for which instructions have been received.

         To the best of the  Company's  knowledge,  as of the  record  date,  no
person owned beneficially more than 5% of the Fund, except as set forth above.

         The  presence in person or by proxy of a majority of the Fund's  shares
entitled to vote is necessary  to  constitute  a quorum for the  transaction  of
business.  For purposes of determining  the presence of a quorum for transacting
business at the Special Meeting, all shares voted at the meeting will be counted
as present whether they vote for, against or abstain. Because Aetna is the legal
owner  of all  Fund  shares,  there  will be a  quorum  at the  Special  Meeting
regardless of how Contract Holders direct Aetna to vote on the Proposal.

         If there are  insufficient  votes to approve the Proposal,  the persons
named as proxies may propose one or more  adjournments of the Special Meeting to
permit  additional  time for the  solicitation  of proxies,  in accordance  with
applicable law.  Adjourned  meetings must be held within a reasonable time after
the date  originally  set for the meeting  (but not more than 120 days after the
record  date).  Solicitation  of  votes  may  continue  to be made  without  any
obligation  to provide any  additional  notice of the  adjournment.  The persons
named as proxies will vote in favor of such adjournment those proxies which they
are  entitled to vote in favor of the  Proposal  and will vote  against any such
adjournment those proxies to be voted against the Proposal.

         The Proposal requires approval by the affirmative vote of a majority of
the outstanding  voting securities of the Fund, which means more than 50% of the
votes entitled to be cast on the Proposal. Abstentions will have the effect of a
"no" vote on the Proposal.

         The number of shares that you may vote is the total of the number shown
on the  authorization  card  accompanying  this Proxy  Statement.  The number of
shares that you are  entitled  to vote is  calculated  according  to the formula
described in the materials relating to your Contract.  Shareholders are entitled
to one vote for each full  share and a  proportionate  vote for each  fractional
share held.  Proxy votes may be revoked by written notice to Aeltus prior to the
Special  Meeting or by attending the Meeting in person and  indicating  that you
want to vote your shares in person.

         Shares of the Fund owned by Aetna  through the general  account will be
voted in the same proportion as shares held by the separate account investing in
the Fund.

         The  appointed  proxies  will  vote in their  discretion  on any  other
business as may properly come before the Special Meeting or any  adjournments or
postponements  thereof.  Additional matters would only include matters that were
not anticipated as of the date of this Proxy Statement.

                             MATTER TO BE ACTED UPON

                               PROPOSAL TO VOTE ON
                        A PLAN OF LIQUIDATION AND PLAN OF
                              SUBSTITUTION FOR THE
                    FUND AND, IN CONNECTION WITH THE PLAN OF
                     LIQUIDATION, PROPOSED AMENDMENTS TO THE
                     CHARTER OF THE COMPANY, AS SET FORTH IN

                              ARTICLES OF AMENDMENT

          The Company's  Board,  including the Directors who are not "interested
persons" of the Company,  as defined by the  Investment  Company Act of 1940, as
amended (the  "Investment  Company  Act"),  have approved and recommend that the
shareholders  of the Fund approve a Plan of Liquidation  for the Fund,  proposed
amendments to the charter of the Company (the  "Charter") in connection with the
Plan of Liquidation,  as set forth in Articles of Amendment appended to the Plan
of  Liquidation  as an  exhibit  ("Articles  of  Amendment"),  and  the  Plan of
Substitution, which is also appended to the Plan of Liquidation as an exhibit.

         Background.  Investment  in the  Fund  is  currently  offered  only  to
separate accounts that fund both annuity and life insurance contracts offered by
Aetna.  Presently,  shares of the Fund are owned only by Aetna's general account
and Aetna's Variable Annuity Account C on behalf of the owners of group deferred
variable  annuity  contracts (as defined above,  the  "Contracts").  On March 1,
2000, the Company's Board decided to recommend to shareholders that they approve
a plan of the  liquidation for the Fund and a related plan of  substitution,  as
discussed below.

         Aetna and the Board  considered  how to best  serve  the  interests  of
Contract Holders in connection with the proposed liquidation.  Specifically,  if
any  Contract  Holder  (or  participant,   if  applicable)   failed  to  provide
alternative  investment  instructions  prior to  Aetna's  receipt  of the Fund's
liquidation proceeds, Aetna would be required to direct the liquidation proceeds
to  the  record  shareholder  which  could  ultimately  result  in  adverse  tax
consequences for Contract  Holders.  To avoid such  consequences,  Aetna and the
Board  recommend  that  shareholders  approve a  substitution  of the subaccount
holding the proceeds of the  liquidated  Fund with the  subaccount  investing in
Aetna  Variable  Encore Fund d/b/a Aetna Money  Market VP ("Aetna  Money  Market
VP").  Contingent upon such approval,  Aetna would then substitute  interests of
Contract  Holders  who did not  exercise  their  transfer  rights  prior  to the
liquidation  with  interests  in shares of Aetna  Money  Market VP,  which is an
existing investment option under the Contracts.

         To limit the number of Contract Holders affected by the liquidation and
subsequent substitution,  Aetna exercised its rights under the Contract to limit
access to the Fund for new Contract  Holders  effective May 15, 2000. As of that
date,  Aetna  accepted  deposits and continues to accept  deposits into the Fund
that are made only pursuant to standing  customer  instructions  (e.g.,  payroll
deduction allocations, dollar cost averaging, etc.) in effect as of the close of
business on May 12, 2000.

         The   attached   authorization   card   seeks  the   approval   of  the
above-described  Proposal by a majority of the outstanding  voting securities of
the Fund.

         Plan of  Liquidation.  The Board has approved a Plan of Liquidation for
the Fund, which is set forth in Exhibit 1 to this proxy statement and summarized
below.

         The Plan will become effective on the date of its adoption and approval
by the affirmative vote of a majority of the outstanding shares of the Fund (the
"Effective Date"). Following this approval, the Fund, in an orderly manner, will
sell all of its  portfolio  securities in order to convert all the Fund's assets
to cash. The Fund will then make a cash  distribution to each shareholder  based
on the  shareholder's  proportionate  share in the net assets of the Fund, after
payment to (or  reservation  of assets for the payment to) all  creditors of the
Fund, in redemption and cancellation of the outstanding shares of the Fund. This
distribution will be made as soon as practicable, but in any event no later than
thirty days after the Effective Date.

         The date on which the Fund makes the  liquidating  distribution  of its
assets to shareholders  and redeems and cancels its  outstanding  shares will be
known as its "Liquidation  Date". (See Section 2 of the Plan of Liquidation.) As
of the close of  business  on the  Liquidation  Date,  the Fund  will  cease its
business as an investment company and will not engage in any business activities
except for the purposes of winding up its business and affairs.

         The  proportionate  interest of each  shareholder  in the assets of the
Fund will be fixed on the basis of that shareholder's  respective holdings as of
the close of business  on the  Liquidation  Date.  On such date the books of the
Fund will be closed. (See Section 4 of the Plan of Liquidation.)

         Aetna owns of record all of the  issued and  outstanding  shares of the
Fund. Upon receipt by Aetna of the liquidating distributions with respect to the
Fund, other than distributions attributable to shares of the Fund owned by Aetna
in a general  account,  Aetna  will  apply  such  liquidating  distributions  in
accordance with the Plan of  Substitution  to purchase,  for the benefit of each
Contract  Holder having an interest in the Fund at the time of its  liquidation,
an  equivalent  interest in Aetna Money Market VP. (See Section 7 of the Plan of
Liquidation.)

         Aeltus will bear all expenses  incurred in connection with carrying out
the Plan of  Liquidation  that the Fund  normally  would not incur if it were to
continue in  business,  including  legal and  auditing  expenses  and  printing,
mailing,  soliciting and  miscellaneous  expenses  arising from the liquidation.
Normal  operating  expenses  of the  Fund  will be borne by the Fund to the same
extent such expenses would have been incurred absent a liquidation. Any expenses
and  liabilities  attributed  to  the  Fund  subsequent  to the  mailing  of the
liquidating  distribution will be borne by Aeltus. (See Section 8 of the Plan of
Liquidation.)

         Under the Plan of Liquidation,  the outstanding shares of the Fund will
be cancelled and reclassified,  as more fully described below. (See the Articles
of  Amendment,  attached to the Plan of  Liquidation  as Exhibit B.) The Plan of
Liquidation  also  provides that the Board shall have the authority to authorize
such  variations from or amendments to the provisions of the Plan of Liquidation
as may be  necessary  or  appropriate  to marshal  the assets of the Fund and to
effect the complete liquidation and termination of the existence of the Fund and
the purposes to be accomplished  by the Plan of  Liquidation.  (See Section 9 of
the Plan of Liquidation.)

         Plan of  Substitution.  Following the liquidation of the Fund, the Plan
of Substitution (attached as Exhibit A to the Plan of Liquidation and summarized
herein)  will be  implemented  by Aetna by  purchasing  with the  proceeds  of a
liquidating  distribution of the Fund, other than distributions  attributable to
shares of the Fund held in a general  account,  for the benefit of each Contract
Holder  having  an  interest  in the  Fund at the  time of its  liquidation,  an
interest  in  Aetna  Money  Market  VP at net  asset  value.  As a  result,  the
substitution  will not affect the value of Contract  Holders'  or  participants'
interests  transferred  from the subaccount  investing in the liquidated Fund to
the investment  option investing in Aetna Money Market VP. (See Section 4 of the
Plan of Substitution.)

         Contract Holders and participants will not incur any fees or charges as
a result of the Plan of  Substitution.  Also,  neither  the  rights of  Contract
Holders and participants, nor the obligations of Aetna under the Contracts, will
be altered in any way.  In  addition,  the  transfer  of the  Contract  Holder's
interests  from the subaccount  investing in the liquidated  Fund as a result of
the Plan of  Substitution  will  not be  counted  as one of the  free  transfers
permitted to Contract Holders and  participants  under certain  Contracts.  (See
Section 5 of the Plan of Substitution.)

         The  expenses  incurred in  connection  with the Plan of  Substitution,
including  legal,  accounting and other fees,  will be paid by Aeltus and/or its
affiliates. (See Section 5 of the Plan of Substitution.)

         Transfer  Rights.  At any time  prior to the Fund's  Liquidation  Date,
Contract Holders (or participants, as applicable) may transfer their interest in
the Fund to any of the other  investment  options  offered under their  Contract
subject to the terms of the relevant separate account  prospectus,  Contract and
retirement  plan,  and no  transfer  fees or  other  charges  will  be  imposed.
Following the  substitution,  Contract  Holders who had any  remaining  interest
transferred from the subaccount  investing in the liquidated Fund to Aetna Money
Market  VP may  transfer  among  any  of the  remaining  investment  options  in
accordance  with the terms of the  Contracts,  also free of any transfer fees or
other charges.

         Contract  Holders  and  participants  should  refer to  their  separate
account prospectus or other applicable disclosure documents for a description of
the other investment  options  available under their Contract prior to and after
the date of the  substitution.  Contract  Holders and  participants may obtain a
prospectus or other disclosure documents for the separate account and applicable
investment   options   free  of  charge  by   contacting   their   local   Aetna
representative,  by writing to Aetna Financial Services,  Annuity Services,  151
Farmington   Avenue,   Hartford,   Connecticut   06156-1277,   or   by   calling
1-800-262-3682.  The  prospectuses  for the  separate  account  and mutual  fund
investment  options are also posted on the Securities and Exchange  Commission's
web site,  http://www.sec.gov,  and may be obtained by contacting the SEC Public
Reference Room at 202-942-8090.

         Surrender  Rights.  In lieu of the transfer rights  discussed above, if
permitted by the  applicable  retirement  plan, if any, and  applicable tax law,
Contract Holders (or  participants,  as applicable) may elect to receive in cash
the value of their  interest  in the Fund prior to the  Liquidation  Date or the
value of their interest actually  transferred from a subaccount investing in the
liquidated Fund to Aetna Money Market VP after the  substitution,  by exercising
their surrender rights under the Contract (such a surrender may have adverse tax
consequences-see  "Federal Tax  Consequences"  below).  If a Contract Holder (or
participant,  as applicable) elects to make a surrender within 30 days after the
date  of the  substitution,  Aetna  has  agreed  to  waive  any  Contract  early
withdrawal charges  attributable to the substituted  amounts that would normally
be imposed on such surrenders.  Aetna's offer to waive early withdrawal  charges
will not apply to amounts  transferred from the other investment  options to the
Fund after April 10, 2000.

         Federal Tax Consequences.  The liquidation and subsequent  substitution
will not create any tax liability for Contract  Holders or  participants.  Also,
Contract  Holders will not incur any tax liability for exercising their transfer
rights. However, if a Contract Holder (or participant,  as applicable) exercises
the surrender right, he or she may incur income tax liability and a tax penalty.
Contract  Holders and  participants  are  encouraged to refer to their  separate
account  prospectus for a discussion of the possible tax consequences  resulting
from a surrender.  ALSO, CONTRACT HOLDERS AND PARTICIPANTS SHOULD SEEK QUALIFIED
TAX ADVICE BEFORE EXERCISING THEIR SURRENDER RIGHTS.

         Articles of Amendment. In connection with the Plan of Liquidation,  and
as described therein,  the Company's Charter will be amended as set forth in the
Articles of Amendment,  as follows: (1) each unissued share of the Fund would be
reclassified as, and would become,  one unissued,  unclassified share of capital
stock of the Company; (2) each issued and outstanding share of the Fund would be
cancelled  and would be  reclassified  as one  unissued,  unclassified  share of
capital stock of the Company;  and (3) the provisions of the Charter designating
and  classifying  shares  of stock of the  Company  into  shares of the Fund and
setting  forth the  attributes  of such shares,  would be deleted.  The proposed
Articles of Amendment  are included as Exhibit B to the Plan of  Liquidation.  A
vote in favor of the  Proposal  will  constitute a vote in favor of the proposed
amendments to the Company's Charter as well as the Plans.

Board's Rationale for Recommending the Plans

         The reasons for liquidating the Fund. The Fund commenced  operations on
December  18, 1997.  The Fund's net assets as of December 31, 1999,  the date of
the Fund's most  recent  fiscal  year end were  $11,434,000.The  Fund has sought
maximum total return, consistent with preservation of capital, primarily through
investment  in a diversified  portfolio of  fixed-income  securities,  which are
chosen to  substantially  replicate the  characteristics  of the Lehman Brothers
Aggregate Bond Index.

         The Fund has been slow to attract assets.  Since inception of the Fund,
Aeltus has observed, based on an examination of investment allocation, that most
Contract Holders have been allocating their purchase  payments to the Contracts'
other investment options.

         Because  the Fund  has not been  able to sell a  sufficient  number  of
shares to lower its operating expense ratio by spreading  expenses over a larger
asset base,  it has had to rely on Aeltus'  contractual  commitment to limit the
Fund's expenses.  These contractual  expense  limitations expire on December 31,
2000.  Aeltus  has  indicated  it may be  unwilling  to  continue  such  expense
limitations  thereafter.  Absent the expense  limitations,  Contract Holders and
participants  with an interest in the Fund would  eventually have to bear all of
the Fund's operating expenses without the benefit of the expense limitation,  at
a time when those expenses are relatively  high and the Fund's net asset size is
small.

         At a March 1, 2000 meeting,  the Board  considered a number of factors,
including  the amount of the Fund's net  assets,  its  expense  ratio  (with and
without the waiver and reimbursement of expenses by Aeltus),  and the likelihood
that  additional  sales of Fund shares  could enable the Fund to attain an asset
level that would sustain an acceptable  expense  ratio.  The Board also reviewed
the expenses  that had been assumed by Aeltus  during the life of the Fund,  the
efforts and expenses of the Company's principal underwriter to distribute shares
of the Fund,  and the  effect of the  operating  expenses  on the  historic  and
anticipated  returns of  shareholders.  The Board considered that Aeltus had not
been able to collect or retain any significant  advisory or administrative  fees
during the life of the Fund,  that there appears to be little prospect that this
would  change in the near  future,  and that Aeltus is not willing to  subsidize
indefinitely the Fund's operations.

         The Board determined that an increase in Fund expenses  attributable to
the likely  discontinuance  or reduction of the fee waiver and  reimbursement of
Fund expenses in the future would adversely affect the Fund's  performance.  The
Board  concluded,  therefore,  that it would be in the  interests  of the Fund's
shareholders  to  liquidate  the  Fund  promptly  in  accordance  with a Plan of
Liquidation.

         Aeltus  and  the  Board  have  regularly   reviewed   developments  and
considered  alternatives  regarding the Fund, including whether a merger with or
transfer  of assets to another  mutual fund would be  possible,  and if it would
produce  desirable  results for  shareholders.  After  reviewing  current market
conditions, the relatively small size of the Fund and the absence of appropriate
merger candidates (i.e.,  funds with investment  objectives  similar to those of
the Fund),  Aeltus and the Board  concluded that  liquidation is preferable to a
merger or transfer of assets.

         Reasons for Substitution.  The Board and Aetna determined that it would
be in the best interest of Contract Holders (and  participants) to liquidate the
Fund in a manner that avoids adverse tax  consequences  for Contract Holders and
participants.  In the absence of transfer instructions or a substitute transfer,
Contract  Holders or participants  might receive a distribution of cash proceeds
from  the  liquidation,  which  could  result  in tax  liability.  The  Plan  of
Substitution  avoids this result by providing a mechanism  for Aetna to transfer
the interests of Contract Holders (or  participants,  if applicable) in the Fund
automatically  to a designated  substitute fund upon  liquidation,  for Contract
Holders (or participants) who have not otherwise given transfer instructions.

         For the foregoing reasons and subject to receipt of a favorable vote of
the Fund's  shareholders  on the  Proposal,  the Fund would be  eliminated as an
investment option under the Contract after the liquidation is effected,  and its
outstanding  shares  redeemed  and  cancelled.  Additionally,  the  interests of
Contract  Holders in the liquidated  Fund would be substituted  with  equivalent
interests in Aetna Money Market VP.

         Reasons for  Recommending  a  Substitution  into Aetna Money Market VP.
Aetna determined,  and the Board agreed, that Aetna Money Market VP would be the
most  appropriate  vehicle  into which to  transfer  the  interests  of Contract
Holders who do not exercise their transfer  rights prior to the Effective  Date.
Aetna Money Market VP is  available  under all the  affected  Contracts  and was
determined to be an appropriate  alternative  because it is designed to preserve
the value of a  shareholder's  investment  and is often used by  investors  as a
temporary investment option. Aetna Money Market VP seeks to provide high current
return,   consistent  with  preservation  of  capital  and  liquidity,   through
investment in high-quality money market  instruments.  In addition,  Aetna Money
Market VP has a lower  expense  ratio as  compared  to that of other  investment
options available under the Contracts.  Contract Holders should consider whether
reallocation  of  their  interest  in the  Fund  to  another  investment  option
available  under their  respective  Contracts  would be  appropriate in light of
their investment goals. See "Transfer Rights" above for more information.

         The  following  chart  compares  the advisory fee rates and the expense
ratios of the Fund and Aetna Money Market VP. It also  illustrates the impact on
the Fund's expenses if Aeltus had not agreed to limit the Fund's expenses during
the period.



                  FOR THE FISCAL YEAR ENDED DECEMBER 31, 1999:

                                                         Ratio of Expenses to
                                                         Average Net Assets
                                         Ratio of Net    Before Reimbursement
                                         Expenses to     and Waiver
                                         Average Net
Fund                      Advisory Fee   Assets


Aetna Money Market VP     .25 %          .34 %                   .34 %

Index Plus Bond Fund      .40 %          .45 %                   .63 %

         For more information,  please refer to the current  prospectus or other
disclosure documents for Aetna Money Market VP and the Fund previously furnished
to you. To request a  prospectus  or other  information,  please  contact  Aetna
Financial Services at the address or number provided on page 6.

Failure to Approve the Proposal

         If the Fund's  shareholders do not approve the Proposal,  the Fund will
continue  to  exist  as  an  investment  option  under  the  Contracts  and  the
substitution  of Contract Holder  interests would not be implemented.  The Board
would then meet to consider  what,  if any,  steps to take in the  interests  of
shareholders.

         For  the  reasons  specified  above,  Aetna  and  the  Company's  Board
recommend  that the Proposal be approved  for the Fund.  Persons  having  voting
interests  in the Fund are  encouraged  to carefully  consider  the  information
contained in the Proxy  Statement and to complete and return the enclosed voting
instruction form.

  THE BOARD OF DIRECTORS RECOMMENDS THAT THE SHAREHOLDERS OF THE FUND VOTE FOR
  THE PLAN OF LIQUIDATION AND PLAN OF SUBSTITUTION AND, IN CONNECTION WITH THE
     PLAN OF LIQUIDATION, PROPOSED AMENDMENTS TO THE CHARTER OF THE COMPANY,
                     AS SET FORTH IN ARTICLES OF AMENDMENT.


                               GENERAL INFORMATION

Investment Adviser, Administrator and Principal Underwriter

         The  investment  adviser  and  administrator  to  the  Fund  is  Aeltus
Investment  Management,  Inc.,  10 State  House  Square,  Hartford,  Connecticut
06103-3602.  Aeltus  is a part of the  Aetna  organization,  and is an  indirect
wholly-owned  subsidiary  of Aetna Inc.,  a health care and  financial  services
company  with stock  listed for  trading  on the New York  Stock  Exchange.  The
Company's principal underwriter is Aetna Life Insurance and Annuity Company, 151
Farmington Avenue, Hartford, Connecticut 06156.

                                 OTHER BUSINESS

         The  management of the Fund knows of no other  business to be presented
at the Special Meeting other than the matter set forth in this Proxy  Statement.
If any other  business  properly comes before the Special  Meeting,  the proxies
will exercise their best judgment in deciding how to vote on such matters.

                              SHAREHOLDER PROPOSALS

         The  Company's  Charter and the By-laws  provide that the Fund need not
hold annual shareholder  meetings,  except as required by the Investment Company
Act.  Therefore,  in the event that the  Proposal is not  approved by the Fund's
shareholders, it is probable that no annual meeting of shareholders will be held
in 2000 or in  subsequent  years  until so  required.  For those  years in which
annual or special shareholder meetings are held, proposals which shareholders of
the Fund intend to present for inclusion in the proxy  materials with respect to
the meeting of  shareholders  must be  received by the Fund within a  reasonable
period of time  before the  solicitation  is made.  The timely  submission  of a
proposal does not guarantee its inclusion.

         Please  complete the enclosed proxy card, as applicable,  and return it
promptly in the enclosed  self-addressed,  postage-paid envelope. You may revoke
your proxy at any time prior to the Special  Meeting by written notice to Aeltus
or by submitting a proxy card bearing a later date.

                                        By Order of the Board of Directors,


                                         Amy R. Doberman
                                         Secretary

<PAGE>


                                    EXHIBIT 1

                         AETNA VARIABLE PORTFOLIOS, INC.
                            Aetna Index Plus Bond VP

                               PLAN OF LIQUIDATION

     This Plan of Liquidation ("Plan") is made by Aetna Variable Portfolios,
Inc. (the "Company"), a corporation organized and existing under the laws of the
State of  Maryland,  with  respect to Aetna Index Plus Bond VP (the  "Fund"),  a
separate  portfolio or series of stock, and a segregated  portfolio of assets of
the Company.  The Fund is a series of an investment company registered under the
Investment  Company Act of 1940, as amended (the "Investment  Company Act"). The
Plan is intended to  accomplish  the  complete  liquidation  of the Fund and the
redemption and  cancellation  of the outstanding  shares thereof,  in conformity
with all provisions of Maryland law and the Company's Charter and By-laws.

         WHEREAS,  due to the small  size of the Fund,  its high  expense  ratio
absent  fee  waivers  and  expense  reimbursements,   the  investment  adviser's
unwillingness  to maintain  indefinitely  the Fund's expenses at current levels,
and the relative lack of investor  interest in the Fund, the Company's  Board of
Directors,  on  behalf  of the  Fund,  has  determined  that  it is in the  best
interests of the Fund and its  shareholders  to liquidate the Fund and to redeem
and cancel the outstanding shares thereof; and

         WHEREAS,  Aetna Life  Insurance  and Annuity  Company  ("Aetna") is the
record  owner of all of the issued and  outstanding  shares of the Fund and owns
shares  either in a general  account  or on behalf of a  separate  account  that
offers  interests in the Fund as an investment  option through  certain  annuity
contracts (the "Contracts") between Aetna and the holders of such Contracts (the
"Contract Holders"); and

         WHEREAS,  Aetna has advised the Company that,  in  connection  with the
liquidation  of the Fund,  Aetna has agreed to remove the Fund as an  investment
option  offered  through  the  Contracts,  and  desires  to  substitute  for the
interests of Contract Holders in the Fund,  shares of Aetna Variable Encore Fund
d/b/a Aetna Money Market VP, an existing  investment option under the Contracts,
pursuant to a proposed Plan of Substitution  substantially  in the form attached
hereto as Exhibit A (the "Plan of Substitution"); and

         WHEREAS,  Aetna has requested that the Company make the  liquidation of
the Fund contingent upon approval of the Plan of Substitution by the affirmative
vote of the holders of a majority of the  outstanding  voting shares of the Fund
to comply with the Plan of  Substitution  in connection  with the liquidation of
Fund, and the Company's Board of Directors has determined that it is in the best
interest of the Fund and its shareholders to do so; and

         WHEREAS, at a meeting of the Board of Directors of the Company on March
1, 2000, the Board of Directors considered and adopted this Plan and the Plan of
Substitution  (collectively  the "Plans") as the method of liquidating  the Fund
and  directed  that  the  Plans be  submitted  to  shareholders  of the Fund for
approval in  accordance  with,  among other  things,  applicable  provisions  of
Maryland law and the Company's Charter and By-laws,  including,  but not limited
to, Section 7, Paragraph (v) of the Company's  Articles of  Incorporation  filed
with the State  Department of Assessments  and Taxation of Maryland on August 4,
1996, and applicable provisions of the Contracts.

         NOW THEREFORE,  the liquidation of the Fund shall be carried out in the
manner hereinafter set forth:

1. Effective Date of Plans. The Plans shall be and become effective with respect
to the Fund only upon the adoption  and approval of both Plans,  at a meeting of
shareholders called for the purpose of voting upon the Plans, by the affirmative
vote of the holders of a majority of the outstanding  voting shares of the Fund.
The day of such adoption and approval of both Plans by  shareholders of the Fund
is hereinafter called the "Effective Date".

2.  Liquidation  Date.  The  date  on  which  the  Fund  makes  the  liquidating
distribution  to  shareholders  described  in Section 7 below,  and  cancels and
redeems its outstanding shares, shall be known as the "Liquidation Date".

3. Cessation of Business.  As of the close of business on the Liquidation  Date,
the Fund shall cease its business as an investment  company and shall not engage
in any  business  activities  except for the purposes of winding up its business
and affairs.

4. Restriction of Transfer and Redemption of Shares. The proportionate interests
of  shareholders  in the assets of the Fund shall be fixed on the basis of their
respective shareholdings as of the close of business on the Liquidation Date. On
such date, the books of the Fund shall be closed.  Thereafter,  unless the books
are  reopened  because the Plans cannot be carried into effect under the laws of
the State of Maryland or otherwise,  the shareholders'  respective  interests in
the Fund's assets shall not be transferable or redeemable.

5.  Liquidation of Assets.  As soon as is reasonable and  practicable  after the
Effective Date, all portfolio securities,  and other assets, if any, of the Fund
shall be converted to cash and cash equivalents.

6. Payment of Debts.  As soon as practicable  after the Effective Date, the Fund
shall  determine  and pay, or set aside in cash  equivalents,  the amount of all
known or reasonably  ascertainable  liabilities of the Fund incurred or expected
to be incurred prior to the date of the liquidating distribution provided for in
Section 7 below, subject to Section 8 below.

7. Liquidating Distribution. As soon as possible after the Effective Date of the
Plans,  and in any event within thirty days  thereafter,  the Fund shall deliver
the following to each  shareholder of record on the Liquidation  Date by mail or
other reasonable  method, in complete  redemption and cancellation of the shares
of the Fund held by such shareholder:  (a) a liquidating  distribution  equal to
the shareholder's  proportionate  interest in the net assets of the Fund and (b)
information concerning the sources of the liquidating  distribution.  Aetna owns
of record all of the issued and outstanding  shares of the Fund. Upon receipt by
Aetna of the  liquidating  distribution  of the Fund,  other than  distributions
attributable  to shares of the Fund owned by Aetna in a general  account,  Aetna
will  apply  such  liquidating  distributions  in  accordance  with  the Plan of
Substitution  to purchase,  for the benefit of each  Contract  Holder  having an
interest in the Fund at the time of its liquidation,  an equivalent  interest in
Aetna Money Market VP.

8.   Management  and  Expenses  of  the  Fund   Subsequent  to  the  Liquidating
Distribution.  The Fund's investment adviser, Aeltus Investment Management, Inc.
("Aeltus"), shall bear all expenses incurred in connection with carrying out the
Plans with  respect to the Fund,  including,  but not limited to, all  printing,
legal and  accounting  fees and the  expenses  of any  reports  to or meeting of
shareholders.  Any expenses and liabilities attributed to the Fund subsequent to
the mailing of the liquidating distribution will also be borne by Aeltus.

9.  Amendment of Plans.  The Board shall have the  authority  to authorize  such
variations from or amendments to the provisions of the Plans as may be necessary
or  appropriate  to  effect  the  marshaling  of Fund  assets  and the  complete
liquidation and  termination of the existence of the Fund, and the  distribution
of the Fund's net assets to shareholders  in redemption and  cancellation of the
outstanding  shares of the  Fund,  in  accordance  with the laws of the State of
Maryland and the purposes to be accomplished by the Plans.

10.  Filings with the State of  Maryland.  In  connection  with the Plans and in
furtherance  thereof,  the Charter of the Company as currently in effect will be
amended  substantially as set forth in Articles of Amendment  attached hereto as
Exhibit B (the  "Articles of  Amendment")  in order to provide for,  among other
things,  the  liquidation  of the assets of the Fund,  the  distribution  of the
proceeds  therefrom to the  shareholders of the Fund and the cancellation of the
outstanding  shares of the Fund.  The  adoption and approval of the Plans by the
shareholders  of  the  Fund  by  the  affirmative  vote  of a  majority  of  the
outstanding voting securities of the Fund shall constitute adoption and approval
by such shareholders of the Articles of Amendment. In the event the shareholders
of the Fund do not approve the Plans,  the  Articles of  Amendment  shall not be
filed.  If  approved,  the  Articles  of  Amendment  shall  be filed  on,  or as
expeditiously as possible after, the Effective Date of the Plans.

                                      AETNA VARIABLE PORTFOLIOS, INC.
                                      On behalf of Aetna Index Plus Bond VP


                                      By: ______________________
                                      J. Scott Fox, President
                                      Accepted:


                                      Aeltus Investment Management, Inc.


                                      By: ______________________
                                      Name:
                                      Title:


<PAGE>

                                    EXHIBIT A

                              PLAN OF SUBSTITUTION



          This Plan of Substitution ("Plan") dated ___________,  2000 is made by
Aetna Life  Insurance  and Annuity  Company  ("Aetna"),  a stock life  insurance
company  organized  under the insurance laws of the State of Connecticut in 1976
and an indirect  wholly-owned  subsidiary of Aetna Inc. Aetna is a broker-dealer
registered  under the Securities  Exchange Act of 1934, as amended,  and acts as
principal  underwriter  with  respect to Variable  Annuity  Account C ("Separate
Account"). The Separate Account is a segregated asset account that funds Aetna's
individual  or  group  deferred  fixed or  variable  annuity  contracts  (each a
"Contract"). The Separate Account is registered with the Securities and Exchange
Commission as a unit investment trust under the Investment  Company Act of 1940,
as amended  (the  "Investment  Company  Act").  Aetna is the  depositor  for the
Separate  Account.  Payments  made to the Separate  Account under a Contract are
allocated  to one or more  subaccounts  (each a  "Subaccount")  of the  Separate
Account.  Each Subaccount invests in shares of an open-end management investment
company  registered  under the  Investment  Company Act. The Plan is intended to
accomplish the substitution of shares of beneficial interest ("shares") of Aetna
Variable  Encore Fund d/b/a Aetna Money  Market VP ("Aetna  Money Market VP") in
which a Subaccount of the Separate  Account  invests,  for shares of Aetna Index
Plus Bond VP ("Fund").  The Fund is a series of Aetna Variable Portfolios,  Inc.
(the "Company"), in which a Subaccount of the Separate Account invests.

         WHEREAS,  the Company's Board of Directors  ("Board"),  with respect to
the Fund,  has  determined  that it is in the best interests of the Fund and its
shareholders to liquidate the Fund pursuant to a Plan of Liquidation; and

         WHEREAS, Aetna has advised the Company's Board that, in connection with
the  liquidation  of the  Fund,  Aetna  has  agreed  to  remove  the  Fund as an
investment  option offered through the Contracts,  and desires to substitute for
the interests of holders of such Contracts (the "Contract Holders") in the Fund,
shares of Aetna Money  Market VP pursuant  to this Plan and has  requested  that
liquidation  of the Fund be made  contingent  upon  approval by the Fund, by the
affirmative  vote of the holders of a majority of the outstanding  voting shares
of the Fund of this Plan, as well as the Plan of Liquidation  (collectively with
the Plan of Substitution,  the "Plans"),  and any Articles of Amendment  related
thereto; and

         WHEREAS,   the  Company  has  advised  Aetna  that  it  will  make  the
liquidation of the Fund contingent upon approval by the affirmative  vote of the
holders of a majority of the outstanding  voting  securities of the Fund of this
Plan, as well as the Plan of  Liquidation  and any  amendments to the Charter of
the Company in connection therewith.

         NOW THEREFORE,  the substitution of a Contract Holder's interest in the
Fund with an interest  in the Aetna Money  Market VP shall be carried out in the
manner hereinafter set forth:

1. Effective Date of Plans. The Plans shall be and become effective with respect
to the Fund only upon the adoption  and  approval of the Plans,  at a meeting of
shareholders called for the purpose of voting upon the Plans, by the affirmative
vote of the holders of a majority of the  outstanding  voting  securities of the
Fund.  The  date of such  adoption  and  approval  of both  Plans by the Fund is
hereinafter called the "Effective Date".

2. Liquidation Date. The date on which the Fund makes a liquidating distribution
to shareholders and redeems and cancels its outstanding shares shall be known as
the "Liquidation Date".

3. Special  Meeting of  Shareholders.  The Company  shall provide to each of the
Contract  Holders  having an interest in shares of the Fund held by the Separate
Account with proxy  materials  containing all  information  necessary to make an
informed  judgment  about the Plans.  Aetna,  as the record  owner of all of the
issued and outstanding  shares of the Fund,  shall vote its shares in accordance
with the instructions received from the Contract Holders. Any shares of the Fund
for which Aetna does not receive  timely voting  instructions,  or which are not
attributable  to  Contract  Holders,   shall  be  voted  in  proportion  to  the
instructions received from all Contract Holders having an interest in the Fund.

4. Substitutions. As soon as possible after the Effective Date of the Plans, and
in any event within thirty days thereafter, the Fund shall deliver the following
to each  shareholder  of  record  on the  Liquidation  Date,  by  mail or  other
reasonable method, in complete  redemption and cancellation of the shares of the
Fund held by such shareholder:

          (a)  A   liquidating   distribution   equal   to   the   shareholder's
               proportionate  interest  in the net  assets of the Fund as of the
               close of business on the Liquidation Date, and


          (b)  Information    concerning   the   source   of   the   liquidating
               distribution, all in accordance with the Plan of Liquidation.

Aetna as the record  owner of all of the issued  and  outstanding  shares of the
Fund, shall, upon receipt of the liquidating  distributions  with respect to the
Fund,  other than  distributions  attributable  to shares of the Fund held in an
Aetna general account,  apply such liquidating  distributions in accordance with
this Plan, to purchase,  for the benefit of each Contract  Holder or participant
having an  interest in the Fund at the time of its  liquidation,  an interest in
Aetna Money Market VP (a  "Substitution").  The Substitution  will take place at
relative net asset value with no change in the amount of any  Contract  Holder's
accumulated  value  or in the  dollar  amount  of his or her  investment  in the
Separate Account.

5. Conditions  Applicable to  Substitution.  The  Substitution is subject to the
following conditions:

          (a)  Contract  Holders shall not incur any fees or charges as a result
               of the Substitution nor shall their rights or Aetna's obligations
               under any Contract be altered.

          (b)  All expenses  incurred in connection with the Substitution  shall
               be  paid  by  Aeltus  Investment  Management,   Inc.  and/or  its
               affiliates.

          (c)  The  Substitution  shall not cause the Contract  fees and charges
               currently being paid by existing Contract Holders or participants
               to  be   greater   after  the   Substitution   than   before  the
               Substitution.

          (d)  The  Substitution  shall not impose any tax liability on Contract
               Holders or participants.

          (e)  The prospectus for each of the registration  statements  affected
               by the  Substitution  will be  updated to  describe  the Plan and
               identify the Fund being  replaced.  Summaries of each  prospectus
               will also be amended to reflect the same information.

          (f)  Contract   Holders   shall  be  furnished   with  notice  of  the
               Substitution in the form of a revised prospectus (some retirement
               plan  participants  will be  furnished  notice  in the  form of a
               separate  document which  describes  material  changes  affecting
               their  account  which is the method of notice  employed  by Aetna
               pursuant to no-action  relief  received from the  Securities  and
               Exchange Commission ("Notice")).  Each prospectus and Notice will
               inform Contract Holders and  participants  that effective May 15,
               2000,  the Fund  Subaccount  will no longer be available  for new
               investment.  The prospectuses  (and Notice) shall inform Contract
               Holders and participants  that they may, at any time prior to the
               Substitution,   transfer  their  accumulation   values  from  the
               Subaccount of the Separate  Account  investing in the Fund to any
               of the other  investment  options  available under their Contract
               without incurring any transfer fees or other charges.

               Each prospectus and Notice shall also inform Contract Holders and
               participants  that, if permitted by this Plan and  applicable tax
               law, they may surrender  amounts  transferred  to the Aetna Money
               Market VP as a result of the Substitution  without payment of the
               associated early withdrawal  charge,  if surrender is made within
               30 days  after  the date of the  Substitution.  Aetna's  offer to
               waive  the early  withdrawal  charge  shall not apply to  amounts
               transferred to the Fund Subaccount from the other  Subaccounts of
               the Separate  Account or from the fixed  account  after April 10,
               2000.

         (g)      As  soon as  practical  after  the  Substitution,  Aetna  will
                  notify, in writing,  all Contract Holders and participants who
                  had values transferred from the Fund Subaccount as a result of
                  the  substitution of their surrender rights and their right to
                  make "free transfers".

         (h)      Upon completion of the Substitution  with respect to the Fund,
                  Aetna  shall  take all  actions  necessary  to  eliminate  the
                  Subaccount of the Separate Account  investing in shares of the
                  Fund.



                                   AETNA LIFE INSURANCE AND ANNUITY COMPANY


                                   By: ___________________________________
                                         Name:
                                        Title:

                                   Accepted:



                                   Aeltus Investment Management, Inc.


                                   By: ______________________
                                   Name:
                                   Title:


<PAGE>

                                    EXHIBIT B

                         AETNA VARIABLE PORTFOLIOS, INC.
                              ARTICLES OF AMENDMENT

             AETNA VARIABLE PORTFOLIOS, INC., a Maryland corporation
registered as an open-end investment company under the Investment Company Act of
1940 and having its principal office in the State of Maryland in Baltimore City,
Maryland  (hereinafter referred to as the "Corporation") hereby certifies to the
State  Department of  Assessments  and Taxation of Maryland  (the  "Department")
that:

         FIRST:  In connection  with and in furtherance of a plan of liquidation
of Aetna  Index  Plus  Bond  VP, a  separate  fund  and  Series  of stock of the
Corporation (the  "Liquidating  Portfolio"),  the Corporation  hereby amends its
Charter as currently in effect (the "Charter") to include the following:

                  A.     As of the Effective Date (as hereinafter defined):

                         (i) each unissued Share of the Liquidating Portfolio of
         stock  of the  Corporation,  par  value  $0.01  per  Share,  is  hereby
         reclassified into, and shall become, one unissued unclassified Share of
         capital stock of the Corporation; and

                         (ii)  the   Corporation   shall  proceed  to  sell  and
         liquidate all assets belonging to the Liquidating  Portfolio and to pay
         from the proceeds thereof all liabilities  belonging to the Liquidating
         Portfolio.   After  payment  of  the   liabilities   belonging  to  the
         Liquidating  Portfolio,  the  remaining  proceeds  from  the  sale  and
         liquidation of the assets belonging to the Liquidating  Portfolio shall
         be  distributed as a liquidating  distribution,  as soon as practicable
         after  the  Effective  Date,  but  in  any  event  within  thirty  days
         thereafter,  among  the  holders  of  the  Shares  of  the  Liquidating
         Portfolio on the date  immediately  preceding the Liquidation  Date (as
         hereinafter  defined),  in proportion to the number of such Shares held
         by them  and  recorded  on the  books of the  Corporation.  The date of
         payment  of such  liquidating  distribution  shall be the  "Liquidation
         Date".

                  B.  Upon  payment  by  the   Corporation  of  the  liquidating
         distribution  on the  Liquidation  Date to the holders of Shares of the
         Liquidating  Portfolio,  each  issued  and  outstanding  Share  of  the
         Liquidating  Portfolio  shall be canceled  and shall cease to be issued
         and  outstanding,  and each such canceled  share shall be  reclassified
         into,  and shall become,  one unissued,  unclassified  share of capital
         stock of the Corporation.

                  C. Upon  cancellation of the issued and outstanding  Shares of
         the Liquidating  Portfolio,  and the  reclassification of such canceled
         Shares  and  all  unissued  Shares  of  the  Liquidating  Portfolio  to
         unissued,  unclassified shares of capital stock of the Corporation, the
         provisions of the Charter  designating and classifying  shares of stock
         of  the  Corporation   into  Shares  of  the   Liquidating   Portfolio,
         establishing  and describing the  preferences,  rights,  voting powers,
         restrictions, limitations as to dividends, qualifications and terms and
         conditions of redemption of Shares of the Liquidating Portfolio and the
         description, and terms and conditions, of the Shares of the Liquidating
         Portfolio  shall be deleted from the Charter of the  Corporation.  Such
         deletions  from the  Charter  of the  Corporation  shall  include  only
         provisions  of the Charter as they relate to Shares of the  Liquidating
         Portfolio, and to the extent which any provisions of the Charter of the
         Corporation relate both to Shares of the Liquidating  Portfolio and one
         or more  other  Series  of  Shares  of stock of the  Corporation,  such
         provisions  shall  remain in the  Charter  but shall be deemed to apply
         only to such one or more other Series of stock of the Corporation.

SECOND:  The amendments to the Charter of the Corporation  herein set forth were
duly advised by the Board of Directors  of the  Corporation  and approved by the
stockholders  entitled to vote thereon, as required by the Charter and Bylaws of
the Corporation and applicable law.

THIRD:  The amendments  set forth herein do not increase the authorized  capital
stock of the Corporation.

FOURTH:  The amendments set forth herein shall become  effective as of the close
of  business  on the date (the  "Effective  Date")  which is the  later of:  (i)
______________,  2000;  and (ii) the date on which these  Articles of Amendment,
having  been duly  advised,  approved,  signed,  acknowledged  and sealed by the
Corporation  as  required by the laws of the State of  Maryland,  and not having
been abandoned  prior to the Effective Date by majority vote of the entire Board
of Directors of the Corporation, are filed for record with the Department.

IN WITNESS WHEREOF, the Corporation has caused these Articles of Amendment to be
executed  in its  name  and on its  behalf  by  its  undersigned  President  and
witnessed  or attested  to by its  undersigned  Secretary  as of the ____ day of
_________________,  2000 and its undersigned  President  acknowledges that these
Articles  of  Amendment  are the act and  deed  of the  Corporation  and,  under
penalties  of perjury,  that the matters and facts set forth  herein are true in
all material respects to the best of his knowledge, information and belief.

                                    AETNA VARIABLE PORTFOLIOS, INC.


                                    By:  ___________________________________
                                         J. Scott Fox, President

                                            ATTEST:




                                         By:  __________________________________
                                              Amy R. Doberman, Secretary


<PAGE>

                               PRELIMINARY COPIES

                 AETNA VARIABLE PORTFOLIOS, INC. (the "Company")

                            Aetna Index Plus Bond VP

                    THIS PROXY CARD IS SOLICITED ON BEHALF OF
                        THE COMPANY'S BOARD OF DIRECTORS

THIS PROXY CARD,  WHEN  PROPERLY  EXECUTED  AND  RETURNED,  WILL BE VOTED IN THE
MANNER DIRECTED HEREIN BY THE  UNDERSIGNED.  IF NO DIRECTION IS MADE, THIS PROXY
CARD WILL BE VOTED FOR APPROVAL OF THE PROPOSAL.

  Please sign exactly as name appears on this card. When the account is in the
 name of joint tenants, all should sign. When signing as administrator, trustee
        or guardian, please give title. If a corporation or partnership,
                sign in entity's name and by authorized persons.



                             X______________________
                              [Signature of Shareholder]

                             Dated: __________________, 2000

Please refer to the Proxy  Statement  for a discussion  of these  matters.  This
proxy  card  is  solicited  in  connection  with  the  special  meeting  of  the
shareholders  of Aetna  Index Plus Bond VP (the  "Fund") to be held at 10:00 am,
Eastern Time, on July 28, 2000, and at any adjournment thereof. THIS PROXY CARD,
WHEN  PROPERLY  EXECUTED,  DIRECTS J. SCOTT FOX AND AMY R.  DOBERMAN TO VOTE THE
SHARES  LISTED ON THE FRONT OF THIS CARD AS DIRECTED AND REVOKES ALL PRIOR PROXY
CARDS.

Please vote by filling in the  appropriate  box below,  as shown,  using blue or
black ink or dark pencil. Do not use red ink.

[   ] [box is filled in solidly]

       THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE "FOR" THE PROPOSAL.

Proposal:  To approve the proposed Plan of Liquidation  and Plan of Substitution
for  the  Fund  and,  in  connection  with  the  Plan of  Liquidation,  proposed
amendments to the Charter of the Company, as set forth in Articles of Amendment.

[   ] FOR                  [   ] AGAINST             [   ] ABSTAIN

IN THEIR  DISCRETION,  THE  PROXIES  ARE  AUTHORIZED  TO VOTE  UPON  SUCH  OTHER
BUSINESS,  INCLUDING ANY ADJOURNMENT OF THE MEETING, AS MAY PROPERLY COME BEFORE
THE MEETING.

<PAGE>

                 AETNA VARIABLE PORTFOLIOS, INC. (the "Company")

                            Aetna Index Plus Bond VP

                THIS AUTHORIZATION CARD IS SOLICITED ON BEHALF OF
                        THE COMPANY'S BOARD OF DIRECTORS

                           VARIABLE ANNUITY ACCOUNT C

 THIS AUTHORIZATION CARD, WHEN PROPERLY EXECUTED AND RETURNED, WILL BE VOTED IN
THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED PARTICIPANT(S) ("CONTRACT HOLDER")
UNDER A VARIABLE  ANNUITY  CONTRACT  FUNDED BY A SEPARATE  ACCOUNT OF AETNA LIFE
INSURANCE  AND  ANNUITY  COMPANY  ("AETNA").  IF  NO  INSTRUCTION  IS  INDICATED
REGARDING  THE PROPOSAL TO BE VOTED ON, AETNA IS INSTRUCTED TO VOTE THE INTEREST
IN THE SEPARATE  ACCOUNT ON SUCH PROPOSAL  PROPORTIONATELY  IN  ACCORDANCE  WITH
INSTRUCTIONS  RECEIVED  FROM OTHER  CONTRACT  HOLDERS.  IF NO  INSTRUCTIONS  ARE
RECEIVED FROM ANY CONTRACT HOLDER, AETNA WILL VOTE FOR THE PROPOSAL.

           Please sign exactly as name appears on this card. When the
         account is in the name of joint tenants, all should sign. When
                 signing as administrator, trustee, plan sponsor
        or guardian, please give title. If a corporation or partnership,
                sign in entity's name and by authorized persons.



                                              X______________________
                                              X______________________

                                             (Signature of Contract Holder)


                                          Dated: __________________, 2000


Please refer to the Proxy  Statement  for a discussion  of these  matters.  This
authorization  card is solicited in connection  with the special  meeting of the
shareholders  of Aetna  Index Plus Bond VP (the  "Fund") to be held at 10:00 am,
Eastern Time,  on July 28, 2000,  and at any  adjournment  thereof (the "Special
Meeting").  THIS AUTHORIZATION  CARD, WHEN PROPERLY  EXECUTED,  DIRECTS AETNA TO
VOTE THE INTEREST OF THE CONTRACT  HOLDER(S)  SIGNING ABOVE IN THE SHARES OF THE
FUND HELD IN THE SEPARATE  ACCOUNT AT THE SPECIAL MEETING AND AT ANY ADJOURNMENT
THEREOF IN THE MANNER  DIRECTED  BELOW WITH RESPECT TO THE MATTERS  DESCRIBED IN
THE NOTICE AND  ACCOMPANYING  PROXY  STATEMENT  FOR SAID MEETING AND REVOKES ALL
PRIOR AUTHORIZATION CARDS.

Please  vote the  shares  listed  on the front of this  card by  filling  in the
appropriate box below, as shown,  using blue or black ink or dark pencil. Do not
use red ink.

[   ] [box is filled in solidly]

       THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE "FOR" THE PROPOSAL.

Proposal:  To approve the proposed Plan of Liquidation  and Plan of Substitution
for  the  Fund  and,  in  connection  with  the  Plan of  Liquidation,  proposed
amendments  to the  Charter  of the  Company,  as set forth in the  Articles  of
Amendment.

[   ] FOR                  [   ] AGAINST             [   ] ABSTAIN

IN THEIR  DISCRETION,  THE  PROXIES  ARE  AUTHORIZED  TO VOTE  UPON  SUCH  OTHER
BUSINESS,  INCLUDING ANY ADJOURNMENT OF THE MEETING, AS MAY PROPERLY COME BEFORE
THE MEETING.




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission